Genmab A/S (GMAB) Stock Price & Analysis
Genmab A/S (GMAB) closed at USD 40 on Thursday, October 22, 2026, up 1.09% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 39.57; the Oct 22, 2026 session ranged USD 39.5–40.17 on volume of 4,685,542 shares. Market capitalization is $24.60B, with a 52-week range of USD 23.62–40.17 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:58 UTC.
Also available as compact Markdown for AI agents: nexqual.com/GMAB.md
Key facts (GMAB)
- Analysts: Buy (mean 2.00 on a 1–5 scale) (12 analysts), mean target USD 45.04 (range 33.5–58).
- Total return with dividends: 1Y +33.9% vs S&P 500 +14.9%; 5Y -14.4% vs S&P 500 +80.3%.
- Next earnings: 2026-11-05, EPS estimate USD 0.31, revenue estimate $8.00B.
Analysts (GMAB)
Consensus Buy (mean 2.00 on a 1–5 scale), 12 analysts; mean target USD 45.04 (low 33.5, high 58).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-07 | Truist Securities | Target raised | Buy | $40 → $45 |
| 2026-10-07 | Guggenheim | Target raised | Buy | $54 → $58 |
| 2026-10-07 | HC Wainwright & Co. | Target raised | Buy | $40 → $50 |
| 2026-10-05 | Guggenheim | Target raised | Buy | $45 → $54 |
| 2026-09-14 | HC Wainwright & Co. | Reiterated | Buy | $40 |
| 2026-08-07 | Guggenheim | Target raised | Buy | $40 → $42 |
| 2026-07-22 | TD Cowen | Upgrade | Hold → Buy | $32 → $43 |
| 2026-07-02 | HC Wainwright & Co. | Target raised | Buy | $38 → $40 |
Total return (dividends reinvested) (GMAB)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +33.9% | -14.4% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +34.0% | -3.0% |
| Volatility (annualized) | 34.1% | 33.5% |
| Max drawdown | -32.5% (Jan 2026→Jun 2026) | -60.9% (Nov 2022→Mar 2025) |
GMAB suppliers, customers and competitors (named in its 20-F)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Pfizer (PFE) | “pharmaceutical manufacturers, which included Genmab collaboration partners AbbVie, J&J, Novartis and Pfizer, outlining” |
| Partner | AbbVie (ABBV) | “pharmaceutical manufacturers, which included Genmab collaboration partners AbbVie, J&J, Novartis and Pfizer, outlining” |
| Partner | Novo Nordisk (NVO) | “These include products that are being developed in collaboration with Lundbeck, Novo Nordisk and” |
| Partner | Seagen | “In October 2011, we entered into a license and collaboration agreement with Seagen, Inc. ("Seagen"), now Pfizer per” |
| Partner | AMGEN INC (AMGN) | “Roche / Amgen Teprotumumab Collaboration” |
| Related party | Eli Lilly (LLY) | “Mr. Hoffmann has held a variety of sales and marketing and executive management positions at Eli Lilly and Company” |
Quoted from the company's 20-F filed Feb 17, 2026.
GMAB analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.31 | $0.35 | -9.1% | $8.00B | 5 |
| Next quarter (ends Dec 2026) | $0.24 | $0.35 | -30.0% | $8.41B | 5 |
| Current fiscal year (ends Dec 2026) | $1.17 | $0.00 | — | $29.76B | 1 |
| Next fiscal year (ends Dec 2027) | $1.51 | $0.00 | — | $35.34B | 2 |
GMAB options: expected move
Options price a move of about ±15.7% (±$6.28) by Nov 20, 2026, which includes earnings on Nov 5, 2026.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 69.8% | ±15.7% |
| Dec 18, 2026 | 56 | 54.3% | ±17.1% |
| Jan 15, 2027 | 84 | 50.8% | ±19.5% |
| Feb 19, 2027 | 119 | 52.4% | ±23.7% |
| May 21, 2027 | 210 | 49.4% | ±29.4% |
30-day implied volatility 56% vs 40.5% realized over the last 30 trading days. Put/call ratio (volume) 2.39. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:58 UTC)
| Price | USD 40 |
|---|---|
| Change | ▲ 1.09% (up) |
| Previous Close | USD 39.57 |
| Open | USD 39.62 |
| Day Range | USD 39.5 – 40.17 |
| 52-Week Range | USD 23.62 – 40.17 |
| Volume | 4,685,542 shares |
| Market Cap | $24.60B |
| Exchange | NMS |
Technical Analysis (GMAB)
Nexqual's technical model rates GMAB "BUY" based on 5 bullish and 1 bearish signals across 127 daily candles, as of October 23, 2026 at 09:58 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 68.81 (neutral) |
| vs SMA50 | Above (USD 34.97) |
| MACD | 1.31 (positive) |
Analyst Ratings (GMAB)
Wall Street analysts rate GMAB "Buy" based on 12 analysts, with a mean price target of USD 45.04 (range USD 33.5–58), per Nexqual as of October 23, 2026 at 09:58 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 12 |
| Mean Target | USD 45.04 |
| High Target | USD 58 |
| Low Target | USD 33.5 |
| Buy / Hold / Sell | 11 / 1 / 0 |
Earnings (GMAB)
| Next Earnings Date | 2026-11-05 |
|---|---|
| Revenue Estimate | $8.00B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.49 vs est 0.33 ▲ beat |
| 2026-03-31 | USD 0.13 vs est 0.19 ▼ miss |
| 2025-12-31 | USD 0.21 vs est 0.37 ▼ miss |
| 2025-09-30 | USD 0.65 vs est 0.45 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:58 UTC.
Financials & Fundamentals (GMAB)
| Total Revenue | $4.13B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +24.90% |
| Gross Margin | +93.03% |
| Operating Margin | +35.24% |
| Profit Margin | +19.07% |
| ROE | +14.00% |
| Debt / Equity | 0.89 |
| Current Ratio | 2.46 |
| Total Cash | $1.51B |
| Total Debt | $5.27B |
Source: Nexqual, October 23, 2026 at 09:58 UTC.
Financial Health Score (GMAB)
Nexqual rates Genmab A/S's overall financial health "Solid" across five dimensions, as of October 23, 2026 at 09:58 UTC.
| Growth | Solid — Revenue +9% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 93%, operating 35% (last 12 months) |
| Balance Sheet | Mixed — $1.51B cash vs $5.27B debt |
| Cash Flow | Solid — Operating cash flow $891M (TTM) |
| Efficiency | Mixed — ROE 14%, ROA 8.8% |
Ownership (GMAB)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +20.53% |
| Shares Outstanding | 614.90M |
| Float | 552.91M |
| Short % of Float | +1.00% |
Source: Nexqual, October 23, 2026 at 09:58 UTC.
Leadership (GMAB)
Genmab A/S is led by Jan G.J. van de Winkel, Co-Founder, President & CEO, per Nexqual as of October 23, 2026 at 09:58 UTC.
| Co-Founder, President & CEO | Jan G.J. van de Winkel |
|---|---|
| Executive VP & CFO | Anthony Pagano |
| Executive VP & Chief Strategy Officer | Martine J. van Vugt |
| Senior Director, Head of Development Business Partnership & Strategy and Director | Martin Schultz |
| VP, Head of Antibody Research Materials & Director | Mijke Zachariasse |
Major Backers & Investors (GMAB)
Notable institutional backers of Genmab A/S include Paradigm Biocapital Advisors LP, Orbis Allan Gray Ltd, Alliancebernstein L.P., according to Nexqual as of October 23, 2026 at 09:58 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Paradigm Biocapital Advisors LP | 2.1% |
| Orbis Allan Gray Ltd | 1.82% |
| Alliancebernstein L.P. | 1.39% |
| Deerfield Management Company, L.P | 1.1% |
| Deep Track Capital, Lp | 0.91% |
| Arrowstreet Capital, Limited Partnership | 0.8% |
| Sofinnova Investments, Inc. | 0.65% |
| Renaissance Technologies | 0.56% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 0.75% |
Source: Nexqual, October 23, 2026 at 09:58 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| INCY | Incyte Corporation | USD 116.93 | ▲ 3.08% |
| BNTX | BioNTech SE | USD 89.67 | ▼ 1.77% |
| ROIV | Roivant Sciences Ltd. | USD 37.45 | ▲ 1.77% |
| INSM | Insmed Incorporated | USD 95.06 | ▲ 1.08% |
| ALNY | Alnylam Pharmaceuticals, Inc. | USD 227.28 | ▲ 0.97% |
| RPRX | Royalty Pharma plc | USD 63.75 | ▲ 2.57% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:58 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt